Last reviewed · How we verify
Plasma rich in growth factors
Plasma rich in growth factors (PRGF) delivers concentrated autologous growth factors and cytokines to promote tissue repair and regeneration.
Plasma rich in growth factors (PRGF) delivers concentrated autologous growth factors and cytokines to promote tissue repair and regeneration. Used for Tissue repair and regeneration in orthopedic and wound healing applications.
At a glance
| Generic name | Plasma rich in growth factors |
|---|---|
| Sponsor | Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias |
| Drug class | Autologous cell/tissue therapy |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine / Orthopedics |
| Phase | Phase 3 |
Mechanism of action
PRGF is prepared from the patient's own blood by isolating platelet-rich plasma and further concentrating growth factors such as PDGF, VEGF, FGF, and IGF-1. These factors are released from activated platelets and promote angiogenesis, cell proliferation, and extracellular matrix deposition to accelerate healing of damaged or degenerative tissues.
Approved indications
- Tissue repair and regeneration in orthopedic and wound healing applications
Common side effects
- Injection site pain or swelling
- Infection at application site
- Allergic reaction
Key clinical trials
- Platelet Rich Plasma Injections In Young And Old Human Subjects (PHASE2)
- Use of Platelet-Rich Plasma to Reduce Sternal Wound Complications After CABG With Median Sternotomy (NA)
- Comparative Effects of CGF and PRP in Impacted Third Molar Surgery (NA)
- Platelet Rich Plasma Combined With Platelet Rich Fibrin in Management of Temporomandibular Joint Osteoarthritis (NA)
- Comparison of the Healing Properties on Corneal Cells of Groth Factor-enriched Plasma and Autologous Serum From Aniridia Patients
- Effects of Steroid, Dextrose Prolotherapy, and Platelet-Rich Plasma Injections in Knee Joint OA Patients (NA)
- i-PRF & Root Surface Biomodification (NA)
- A Prospective Randomized Double Blinded Controlled Trial of Non-Operative Management of TFCC Injuries (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: